Lyondellbasell Industries N.V
LYONDELLBASELL INDUSTRIES N.V.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$30.2B
Operating marginCalculated
-1.4%
Net assets to total assetsCalculated
29.7%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★☆☆☆☆position among all companies
-1.4%
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-10.1%
Capital efficiency
Could not be retrieved
Revenue and profit
Performance, financial position and capital allocation
Lyondellbasell Industries N.V
Recent performance trends
Lyondellbasell Industries N.V
Cash flow trends
Consolidated indicators (8 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$46.2 billion | US$50.5 billion | US$33.3 billion | US$33.4 billion | US$30.2 billion |
| Operating income | US$6.8 billion | US$5.1 billion | US$2.7 billion | US$1.9 billion | US$-0.4 billion |
| Total assets | US$36.7 billion | US$36.4 billion | US$37.0 billion | US$35.7 billion | US$34.0 billion |
| Shareholders' equity | US$11.9 billion | US$12.6 billion | US$12.9 billion | US$12.5 billion | US$10.1 billion |
| Net cash provided by (used in) operating activities | US$7.7 billion | US$6.1 billion | US$4.9 billion | US$3.8 billion | US$2.3 billion |
| Net cash provided by (used in) investing activities | US$-1.5 billion | US$-2.0 billion | US$-1.8 billion | US$-1.9 billion | US$-1.8 billion |
| Net cash provided by (used in) financing activities | US$-6.4 billion | US$-3.4 billion | US$-1.9 billion | US$-1.9 billion | US$-0.5 billion |
| Cash and cash equivalents | US$1.5 billion | US$2.2 billion | US$3.4 billion | US$3.4 billion | US$3.4 billion |
Revenue scale in the same industry
Lyondellbasell Industries N.V
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 5 companies
- 9 DOWFY Dec 2025 US$40.0B
- 10 AmgenFY Dec 2025 US$36.8B
- 11 Lyondellbasell Industries N.VThis companyFY Dec 2025 US$30.2B
- 12 Gilead SciencesFY Dec 2025 US$29.4B
- 13 COLGATE-PALMOLIVEFY Dec 2025 US$20.4B
- … 43 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$1.9 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$3.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-1.8 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$2.3 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$1.4 billion | Consolidated | Disclosed |
| Dividends paid | US$1.8 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$10.1 billion | Consolidated | Disclosed |
| Non-controlling interests | US$11.00 million | Consolidated | Disclosed |
| Net assets | US$10.1 billion | Consolidated | Disclosed |
| Net sales | US$30.2 billion | Consolidated | Disclosed |
| Operating income | US$-0.4 billion | Consolidated | Disclosed |
| Total assets | US$34.0 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0.2 billion | Consolidated | Disclosed |
| Operating margin | -1.4% | Consolidated | Calculated |
| Net assets to total assets | 29.7% | Consolidated | Calculated |
| Net margin | Cannot be calculated | Not applicable | Not calculated (no net income in this year's 10-K) |
| Return on equity | Cannot be calculated | Not applicable | Not calculated (no net income in this year's 10-K) |